Guggenheim Reaffirms “Buy” Rating for Oruka Therapeutics (NASDAQ:ORKA)

Oruka Therapeutics (NASDAQ:ORKA)‘s stock had its “buy” rating reaffirmed by equities research analysts at Guggenheim in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $200.00 target price on the stock. Guggenheim’s price target suggests a potential upside of 93.28% from the stock’s previous close.

A number of other research firms have also recently commented on ORKA. UBS Group upped their price objective on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the company a “buy” rating in a research report on Wednesday, July 1st. Barclays lifted their target price on Oruka Therapeutics from $78.00 to $160.00 and gave the stock an “overweight” rating in a report on Monday, April 27th. Wall Street Zen upgraded Oruka Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Piper Sandler restated an “overweight” rating and issued a $180.00 price target on shares of Oruka Therapeutics in a report on Tuesday, June 2nd. Finally, BTIG Research reaffirmed a “buy” rating and set a $151.00 price target on shares of Oruka Therapeutics in a research report on Tuesday. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $134.30.

Oruka Therapeutics Stock Down 1.6%

NASDAQ ORKA traded down $1.67 on Tuesday, reaching $103.47. The company had a trading volume of 50,193 shares, compared to its average volume of 1,138,098. Oruka Therapeutics has a 52 week low of $13.06 and a 52 week high of $107.55. The stock’s 50 day moving average is $83.59 and its 200-day moving average is $60.75. The stock has a market cap of $6.24 billion, a price-to-earnings ratio of -53.29 and a beta of -0.34.

Oruka Therapeutics (NASDAQ:ORKA) last issued its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). As a group, analysts forecast that Oruka Therapeutics will post -2.06 EPS for the current year.

Insider Transactions at Oruka Therapeutics

In other news, SVP Arjun Agarwal sold 10,290 shares of the business’s stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $59.07, for a total value of $607,830.30. Following the sale, the senior vice president directly owned 16,406 shares in the company, valued at $969,102.42. The trade was a 38.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,947 shares of the company’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $69.28, for a total value of $550,568.16. Following the transaction, the insider directly owned 32,718 shares of the company’s stock, valued at $2,266,703.04. This represents a 19.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 188,406 shares of company stock worth $12,019,683 in the last 90 days. Company insiders own 23.49% of the company’s stock.

Institutional Investors Weigh In On Oruka Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Moody Aldrich Partners LLC bought a new position in Oruka Therapeutics in the fourth quarter valued at approximately $3,844,000. Y Intercept Hong Kong Ltd bought a new stake in shares of Oruka Therapeutics during the 1st quarter worth approximately $1,811,000. SG Americas Securities LLC acquired a new stake in shares of Oruka Therapeutics in the 4th quarter valued at approximately $251,000. Perceptive Advisors LLC boosted its holdings in shares of Oruka Therapeutics by 16.4% in the 4th quarter. Perceptive Advisors LLC now owns 1,476,501 shares of the company’s stock valued at $44,753,000 after buying an additional 208,480 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its stake in shares of Oruka Therapeutics by 18.3% in the first quarter. The Manufacturers Life Insurance Company now owns 72,563 shares of the company’s stock valued at $3,559,000 after buying an additional 11,205 shares in the last quarter. Institutional investors and hedge funds own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.